Literature DB >> 2818117

Refractory potassium repletion due to cisplatin-induced magnesium depletion.

M Rodriguez1, D L Solanki, R Whang.   

Abstract

Cisplatin is a common cause of hypomagnesemia and hypokalemia due to renal magnesium (Mg) and potassium (K) losses. Magnesium plays an important role in the maintenance of intracellular K. An unrecognized and untreated Mg depletion can lead to a refractory K repletion. We describe two patients with hypomagnesemia-associated refractory hypokalemia following cisplatin following cisplatin therapy. Potassium supplementation failed to replace the K deficit. Profound hypokalemia persisted until hypomagnesemia was recognized and corrected. In neither patient was the concurrent hypomagnesemia recognized until the 11th and 9th hospital days. These two cases demonstrated the association of a refractory K repletion and an Mg deficiency. Thus, both serum K ion and Mg levels should routinely be assessed in patients who require cisplatin therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2818117

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study.

Authors:  A Surendiran; N Balamurugan; K Gunaseelan; Shahid Akhtar; K S Reddy; C Adithan
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

3.  Hypokalemia secondary to capecitabine: a hidden toxicity?

Authors:  Muhammad Wasif Saif; Mohammad Houman Fekrazad; Leslie Ledbetter; Robert B Diasio
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

4.  Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer.

Authors:  Y K Lee; D M Shin
Journal:  Korean J Intern Med       Date:  1992-07       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.